TARGETED THERAPY OF NSCLC WITH EGFR ACTIVATING MUTATIONS IMPROVES THE QUALITY OF LIFE OF PATIENTS

Conversion of the incurable disease in the chronic form and improvement of the life quality parameters on the background of appearance of new drugs is of specific importance for patients with NSCLC with activating mutations. “ESMO thinks that treatment of patients with wide-spread and incurable canc...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: T. Y. SEMIGLAZOVA, A. S. ZHABINA, А. V. BELYAEVA, V. A. KLUGE, K. V. USOVA, D. H. LATIPOVA, G. M. TELETAEVA, A. V. NOVIK, A. I. SEMENOVA, S. A. PROTSENKO
Médium: Artigo
Jazyk:Russo
Vydáno: Remedium Group LLC 2016-12-01
Edice:Медицинский совет
Témata:
itk egfr
pfs
quality of life
nsclc mut +
afatinib
On-line přístup:https://www.med-sovet.pro/jour/article/view/1406
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky